NYSE MKT
AGE

AgeX Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

AgeX Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.68
Today's High:
$0.7995
Open Price:
$0.78
52W Low:
$0.5
52W High:
$1.12
Prev. Close:
$0.76
Volume:
14291

Company Statistics

Market Cap.:
$23.18 million
Book Value:
-0.398
Revenue TTM:
$53000
Operating Margin TTM:
-13320.76%
Gross Profit TTM:
$125000
Profit Margin:
0%
Return on Assets TTM:
-198.99%
Return on Equity TTM:
0%

Company Profile

AgeX Therapeutics Inc had its IPO on 2018-11-29 under the ticker symbol AGE.

The company operates in the Healthcare sector and Biotechnology industry. AgeX Therapeutics Inc has a staff strength of 5 employees.

Stock update

Shares of AgeX Therapeutics Inc opened at $0.78 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.68 - $0.8, and closed at $0.68.

This is a -10.53% slip from the previous day's closing price.

A total volume of 14,291 shares were traded at the close of the day’s session.

In the last one week, shares of AgeX Therapeutics Inc have slipped by -4.23%.

AgeX Therapeutics Inc's Key Ratios

AgeX Therapeutics Inc has a market cap of $23.18 million, indicating a price to book ratio of 12.9556 and a price to sales ratio of 408.1114.

In the last 12-months AgeX Therapeutics Inc’s revenue was $53000 with a gross profit of $125000 and an EBITDA of $-6928000. The EBITDA ratio measures AgeX Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, AgeX Therapeutics Inc’s operating margin was -13320.76% while its return on assets stood at -198.99% with a return of equity of 0%.

In Q3, AgeX Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 62.5%.

AgeX Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AgeX Therapeutics Inc’s profitability.

AgeX Therapeutics Inc stock is trading at a EV to sales ratio of 673.0465 and a EV to EBITDA ratio of -4.9988. Its price to sales ratio in the trailing 12-months stood at 408.1114.

AgeX Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$2.01 million
Total Liabilities
$8.81 million
Operating Cash Flow
$0.00
Capital Expenditure
$0
Dividend Payout Ratio
0%

AgeX Therapeutics Inc ended 2024 with $2.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $2.01 million while shareholder equity stood at $-15104000.00.

AgeX Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $8.81 million in other current liabilities, 4000.00 in common stock, $-113507000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $466000.00 and cash and short-term investments were $466000.00. The company’s total short-term debt was $7,298,000 while long-term debt stood at $8.35 million.

AgeX Therapeutics Inc’s total current assets stands at $1.19 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1000.00 compared to accounts payable of $612000.00 and inventory worth $0.

In 2024, AgeX Therapeutics Inc's operating cash flow was $0.00 while its capital expenditure stood at $0.

Comparatively, AgeX Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.68
52-Week High
$1.12
52-Week Low
$0.5
Analyst Target Price
$

AgeX Therapeutics Inc stock is currently trading at $0.68 per share. It touched a 52-week high of $1.12 and a 52-week low of $1.12. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.75 and 200-day moving average was $0.65 The short ratio stood at 10.54 indicating a short percent outstanding of 0%.

Around 4348.6% of the company’s stock are held by insiders while 1278.2% are held by institutions.

Frequently Asked Questions About AgeX Therapeutics Inc

The stock symbol (also called stock or share ticker) of AgeX Therapeutics Inc is AGE

The IPO of AgeX Therapeutics Inc took place on 2018-11-29

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$50.39
0.31
+0.62%
$9.21
0.01
+0.11%
$627.7
-33.15
-5.02%
$20.38
0.38
+1.9%
$32.6
0.43
+1.34%
Indigo Paints Ltd (INDIGOPNTS)
$1529.25
-50.8
-3.22%
$272.2
-4.4
-1.59%
Mazda Limited (523792)
$1068.6
-44.7
-4.02%
$153
1.62
+1.07%
$146.77
-0.08
-0.05%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company’s lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Address

1101 Marina Village Parkway, Alameda, CA, United States, 94501